{"id":"contrast-agent-iodixanol","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Allergic reactions (mild to severe)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1200507","moleculeType":"Unknown","molecularWeight":"1550.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iodixanol is an osmotically balanced contrast agent with an osmolality equal to blood plasma (~290 mOsm/kg), which reduces the osmotic gradient and associated physiological stress compared to hyperosmolar agents. The iodine atoms in its molecular structure have high atomic number and density, making them radiopaque and allowing visualization of vascular and organ structures during radiographic imaging procedures.","oneSentence":"Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs by absorbing X-rays due to its high iodine content.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:47.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coronary angiography and ventriculography"},{"name":"Peripheral vascular angiography"},{"name":"Computed tomography imaging"},{"name":"Urography and other radiographic procedures"}]},"trialDetails":[{"nctId":"NCT06176248","phase":"NA","title":"Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis","status":"RECRUITING","sponsor":"CHU de Reims","startDate":"2024-10-11","conditions":"Adhesive Capsulitis","enrollment":62},{"nctId":"NCT04566185","phase":"NA","title":"Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-12-16","conditions":"Glioblastoma","enrollment":14},{"nctId":"NCT00558142","phase":"PHASE4","title":"Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2008-02","conditions":"Radiocontrast-induced Nephropathy","enrollment":107},{"nctId":"NCT03689946","phase":"PHASE3","title":"Effect of Evolocumab on Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-03-19","conditions":"Cardiovascular Disease, Hyperlipidemia","enrollment":55},{"nctId":"NCT05862220","phase":"","title":"Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism","status":"COMPLETED","sponsor":"Zulekha Hospitals","startDate":"2020-12-14","conditions":"D-Dimer as an Early Detector of Pulmonary Embolism","enrollment":28},{"nctId":"NCT03631771","phase":"PHASE4","title":"Pediatric Risk of Hypothyroidism With Iodinated Contrast Media","status":"WITHDRAWN","sponsor":"GE Healthcare","startDate":"2022-03","conditions":"Hypothyroidism","enrollment":""},{"nctId":"NCT03671603","phase":"","title":"Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2018-11-05","conditions":"Coronary Artery Disease, ST-segment Elevation Myocardial Infarction","enrollment":2755},{"nctId":"NCT05065073","phase":"PHASE4","title":"Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography","status":"UNKNOWN","sponsor":"Minneapolis Heart Institute Foundation","startDate":"2021-09-30","conditions":"Coronary Artery Disease, Contrast Media Reaction","enrollment":62},{"nctId":"NCT01136876","phase":"PHASE4","title":"Kidney Damage in Patients With Moderate Fall in eGFR","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-11","conditions":"Coronary Artery Stenosis","enrollment":57},{"nctId":"NCT03914950","phase":"NA","title":"TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2014-02-07","conditions":"Pancreatic Cancer, Pancreatitis, IPMN","enrollment":174},{"nctId":"NCT04342455","phase":"NA","title":"A Low-dose Radiation and Contrast Agent Exposure Protocol for Coronary CTA in Diabetic Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2018-10-07","conditions":"Coronary Artery Disease","enrollment":400},{"nctId":"NCT03119662","phase":"PHASE4","title":"A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2018-02-08","conditions":"Chronic Kidney Diseases","enrollment":4},{"nctId":"NCT00335101","phase":"PHASE4","title":"Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography","status":"WITHDRAWN","sponsor":"GE Healthcare","startDate":"2006-06","conditions":"Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus","enrollment":""},{"nctId":"NCT00335335","phase":"PHASE3","title":"Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2006-05","conditions":"Coronary Artery Disease","enrollment":89},{"nctId":"NCT00348608","phase":"PHASE3","title":"Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2006-06","conditions":"Coronary Artery Disease","enrollment":66},{"nctId":"NCT00793182","phase":"PHASE4","title":"Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography","status":"TERMINATED","sponsor":"Guerbet","startDate":"2009-01","conditions":"Renal Impairment","enrollment":6},{"nctId":"NCT01843426","phase":"NA","title":"Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2013-02","conditions":"Aortic Valve Stenosis","enrollment":40},{"nctId":"NCT01188486","phase":"NA","title":"Pulmonary Interstitial Lymphography in Early Stage Lung Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-08","conditions":"Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)","enrollment":12},{"nctId":"NCT01534975","phase":"NA","title":"Comparison of Contrast Agents During CT Angiography","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2012-01","conditions":"Contrast Enhancement on Cardiac CT","enrollment":513},{"nctId":"NCT03333330","phase":"PHASE3","title":"IMaging Della PLAcca Carotidea","status":"COMPLETED","sponsor":"Enrico Ammirati","startDate":"2012-04","conditions":"Carotid Artery Plaque, Atherosclerosis, Ischemic Stroke","enrollment":75},{"nctId":"NCT02282540","phase":"NA","title":"Novel Imaging of the Eustachian Tube; Patient Study","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2015-05","conditions":"Otitis Media With Effusion, Eustachian Tube Disorder","enrollment":24},{"nctId":"NCT02476526","phase":"PHASE4","title":"Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease","status":"COMPLETED","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2008-09","conditions":"Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis","enrollment":50},{"nctId":"NCT01146639","phase":"NA","title":"DynaCT in Preoperative Imaging Before Insertion of Stentgraft","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2008-08","conditions":"Abdominal Aortic Aneurysm","enrollment":20},{"nctId":"NCT02991742","phase":"","title":"Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)","status":"UNKNOWN","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2016-12","conditions":"Acute Kidney Failure","enrollment":2262},{"nctId":"NCT01935141","phase":"NA","title":"Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli","status":"WITHDRAWN","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2016-01","conditions":"Multiple Pulmonary Emboli","enrollment":""},{"nctId":"NCT01848899","phase":"PHASE4","title":"Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2013-02","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT02718521","phase":"NA","title":"Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-03","conditions":"Cardio-Renal Syndrome","enrollment":400},{"nctId":"NCT01786824","phase":"PHASE3","title":"Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2014-12","conditions":"Acute Kidney Injury, Renal Insufficiency","enrollment":9},{"nctId":"NCT01908309","phase":"EARLY_PHASE1","title":"Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship","status":"COMPLETED","sponsor":"Azienda Sanitaria Locale 9, Grosseto","startDate":"2013-04","conditions":"Contrast Induced Acute Kidney Injury","enrollment":150},{"nctId":"NCT02405377","phase":"NA","title":"Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2014-02","conditions":"Cardio-Renal Syndrome","enrollment":264},{"nctId":"NCT00209417","phase":"PHASE4","title":"Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2005-06","conditions":"Renal Insufficiency, Diabetes Mellitus","enrollment":656},{"nctId":"NCT01549379","phase":"NA","title":"Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2013-07","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT02063594","phase":"PHASE1","title":"Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers","status":"TERMINATED","sponsor":"Marval Pharma Ltd.","startDate":"2014-03","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT02171247","phase":"PHASE3","title":"Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-04","conditions":"Coronary Computed Tomographic Angiography","enrollment":35},{"nctId":"NCT01475097","phase":"PHASE4","title":"Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2011-10","conditions":"Drug Safety","enrollment":255},{"nctId":"NCT01376089","phase":"PHASE4","title":"Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2011-05","conditions":"Patient Comfort and Safety","enrollment":304},{"nctId":"NCT01580046","phase":"PHASE4","title":"Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction","status":"UNKNOWN","sponsor":"Yong Huo","startDate":"2012-04","conditions":"Kidney Failure, Chronic","enrollment":200},{"nctId":"NCT01137786","phase":"PHASE4","title":"Kidney Damage in Patients With Normal eGFR","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2010-12","conditions":"Coronary Artery Stenosis","enrollment":49},{"nctId":"NCT01402219","phase":"PHASE4","title":"Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients","status":"TERMINATED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2008-11","conditions":"Chronic Renal Disease","enrollment":204},{"nctId":"NCT01737138","phase":"NA","title":"Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2012-11","conditions":"Chronic Kidney Disease","enrollment":100},{"nctId":"NCT01004770","phase":"PHASE1, PHASE2","title":"Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2009-10","conditions":"Healthy","enrollment":50},{"nctId":"NCT00926562","phase":"PHASE4","title":"A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-02","conditions":"Kidney Failure, Chronic","enrollment":592},{"nctId":"NCT00885768","phase":"","title":"Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization","status":"COMPLETED","sponsor":"Imam Khomeini Hospital","startDate":"2008-07","conditions":"Renal Artery Stenosis","enrollment":146},{"nctId":"NCT00827788","phase":"PHASE4","title":"Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Ospedale San Donato","startDate":"2008-12","conditions":"Contrast Induced Nephropathy, Acute Myocardial Infarction","enrollment":432},{"nctId":"NCT00823628","phase":"PHASE4","title":"Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-02","conditions":"Chronic Renal Insufficiency, Coronary Angiography","enrollment":420},{"nctId":"NCT00390585","phase":"PHASE4","title":"Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis","enrollment":324},{"nctId":"NCT00479024","phase":"","title":"Follow-up Study to Previous CARE Trial","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2007-06","conditions":"Moderate to Severe Chronic Kidney Disease","enrollment":294},{"nctId":"NCT00493584","phase":"NA","title":"Acute Balloon Angioplasty vs. Traditional Early Invasive Treatment of Non-ST-Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2008-03","conditions":"Myocardial Infarction","enrollment":14},{"nctId":"NCT00209430","phase":"PHASE4","title":"Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-08","conditions":"Coronary Artery Disease, Renal Impairment","enrollment":408},{"nctId":"NCT00247325","phase":"PHASE4","title":"RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2004-01","conditions":"Kidney Failure","enrollment":""},{"nctId":"NCT00289029","phase":"PHASE4","title":"A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2005-07","conditions":"CIN","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"contrast agent (iodixanol)","genericName":"contrast agent (iodixanol)","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iodixanol is a diagnostic agent used in various medical conditions, including coronary artery disease, acute kidney injury, and glioblastoma, as indicated by ClinicalTrials.gov. According to ChEMBL, its mechanism of action is as a diagnostic agent, but its modality is unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}